HoloMD has closed the first tranche of its $3 million seed round, securing $1.6 million to accelerate the development of its AI-powered Remote Therapeutic Monitoring platform for psychiatry. The Rockville-based company will host a virtual investor briefing on November 11 at 12:00 p.m. ET to provide updates on clinical deployment progress and upcoming growth initiatives.
The new funding will support the expansion of Dr. Holo, an AI-enabled companion that works alongside clinicians by engaging patients between visits through structured check-ins and brief interventions. The platform captures emotional, behavioral, and contextual signals, summarizing them into actionable clinical insights while supporting Remote Therapeutic Monitoring reimbursement workflows. Licensed clinicians review all patient interactions to ensure safety, accuracy, and empathetic communication.
The system is built on more than 40 years of psychiatric expertise and is designed to help clinicians improve outcomes, reduce administrative burden, and create financially sustainable support between appointments. Over the past 15 months, HoloMD has moved from concept to active deployments with validated reimbursement models across multiple commercial payers. The company reports strong early results with positive clinician response and consistent patient engagement. With core platform infrastructure, billing workflows, and live revenue in place, HoloMD is now preparing to expand into additional practices and markets.
Key investment highlights include leadership experience, clinical expertise, and momentum in intellectual property. The company emphasizes the combination of automation and human oversight and has structured workflows to comply with CPT codes for Remote Therapeutic Monitoring.
- Proven leadership experience, including three prior healthcare exits totaling $450 million.
- Clinically founded platform drawing from decades of psychiatric practice.
- Validated reimbursement through Medicare and commercial payers.
- Human-supervised AI engagement is designed to ensure patient safety and relational care.
- Patent-pending platform supported by a growing national deployment pipeline.
Founded in July 2024, HoloMD’s platform is fully HIPAA- and HITECH-compliant and currently supports Medicare RTM billing. The company holds multiple provisional patents, one utility patent pending, and several trademarks in progress.
KEY QUOTE:
“Built by psychiatrists for psychiatrists and PMHNPs, our mission is to extend healing beyond the clinic walls. Dr. Holo engages patients every day, surfaces what’s going well and what isn’t, and equips clinicians with actionable insights to improve diagnosis and treatment, while enabling care between visits that is eligible for reimbursement.”
Bruce A. Kehr, MD, Founder & CEO of HoloMD
“HoloMD sits at the intersection of better outcomes and better economics. By aligning eligible RTM reimbursement with continuous patient support, we have created a sustainable model that is designed to help clinicians improve outcomes while scaling care sustainably.”
Jim Pearson, Executive Chairman of HoloMD
